Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting
Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity. New immunomodulatory agents offer the possibility of limiting GC exposure. To assess the comparative benefits of…Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting
Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar
Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Adverse Effects – the Patient Perspective
Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…Abstract Number: 1199 • 2016 ACR/ARHP Annual Meeting
A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium
Background/Purpose: Methotrexate (MTX) is associated with a rare but potentially life-threatening lung disease, MTX-pneumonitis (MTX-P). MTX-P is an idiosyncratic hypersensitivity reaction to MTX inducing inflammation,…Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 10
- Next Page »